http://orcid.org/0000-0003-3281-2081
REFERENCES
- Abboud, M., J. Laver, and C. A. Blau. 1998. Granulocytosis causing sickle-cell crisis. The Lancet 351(9107): 959.
- Adler, B. K., D. E. Salzman, M. H. Carabasi, W. P. Vaughan, V. V. Reddy, and J. T. Prchal. 2001. Fatal sickle cell crisis after granulocyte colony-stimulating factor administration. Blood 97(10): 3313–3314.
- Boulad, F., T. Shore, K. van Besien, et al. 2018. Safety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle cell disease: Interim results. Haematologica 103(9): 1577–1577.
- Braunstein, J. B., N. S. Sherber, S. P. Schulman, E. L. Ding, and N. R. Powe. 2008. Race, medical researcher distrust, perceived harm, and willingness to participate in cardiovascular prevention trials. Medicine 87(1): 1–9.
- Esrick, E. B., J. P. Manis, H. Daley, et al. 2018. Successful hematopoietic stem cell mobilization and apheresis collection using plerixafor alone in sickle cell patients. Blood Advances 2(19): 2505–2512.
- Lagresle-Peyrou, C., F. Lefrère, E. Magrin, et al. 2018. Plerixafor enables safe, rapid, efficient mobilization of hematopoietic stem cells in sickle cell disease patients after exchange transfusion. Haematologica 103(5): 778–786.
- Scharff, D. P., K. J. Mathews, P. Jackson, J. Hoffsuemmer, E. Martin, and D. Edwards. 2010. More than Tuskegee: Understanding mistrust about research participation. Journal of Health Care for the Poor and Underserved 21(3): 879–897.
- Sewell, A. A. 2015. Disaggregating ethnoracial disparities in physician trust. Social Science Research 54: 1–20.
- Wilfond, B. S., D. M. Duenas, and L. M. Johnson. 2020. Greater than minimal risk, no direct benefit: Bridging drug trials and novel therapy in pediatric populations. The American Journal of Bioethics 20(4): 102–103.